QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2− metastatic breast cancer receiving a CDK4/6 inhibitor in first line

QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2− metastatic breast cancer receiving a CDK4/6 inhibitor in first line

Abstract Background The risk of drug-induced corrected QT interval (QTc) prolongation is an important consideration in clinical decision-making for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (mBC). This retrospective...

Full description

Saved in:
Bibliographic Details
Main Authors: Susan Dent, Heather Moore, Michael Fradley, Chloe Grace Rose, Stella Stergiopoulos, Connie Chen, Benjamin Li, Avirup Guha
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Cardio-Oncology
Subjects:
QTc-prolonging medication
Torsades de Pointes
Metastatic breast cancer
CDK4/6 inhibitor
HR+/HER2−
Online Access:https://doi.org/10.1186/s40959-025-00364-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s40959-025-00364-z

Similar Items